A clinical trial to evaluate the efficacy of Neermulli kudineer in patients having highBP and protein in urine.

Clinical validation of Neermulli Kudineer in the reduction of Albuminuria in patients with Uratha Pithavatham (Essential Hypertension)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2017/08/009568

Enrollment

Registered

2017-08-31

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Patients with Uratha Pithavatham (Essential Hypertension) having Albuminuria

Interventions

Intervention1: Neermulli Kudineer: 50 ml of Neermulli kudineer is administered twice a day for 3 months Control Intervention1: Nil: Nil

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients with mild to moderate essential Hypertension (JNC VII) 2. Patients with mild to moderately increased albuminuria (A1 â?? A2 category, ACR â?? 30 â?? 300 mg/g) 3. Patients willing and able to provide informed consent.

Exclusion criteria

Exclusion criteria: 1. Acute systemic febrile / infection diseases or infections / inflammatory renal diseases. 2. Chronic Auto immune disease. 3. Diabetes mellitus. 4. Secondary Hypertension. 5. Renal artery Stenosis 6. Recent history of Myocardial infarction / stroke 7. Pregnant and lactating females 8. Patient who are unwilling or unable to comply with the trial protocol

Design outcomes

Primary

Measure	Time frame
Reduction in urinary albumin excretion from the base line. 20 % reduction in ACR â?? Mild improvement 30 % reduction in ACR â?? Moderate improvement 30% reduction in ACR â?? Marked improvementTimepoint: Reduction in urinary albumin excretion from the base line. 20 % reduction in ACR â?? Mild improvement 30 % reduction in ACR â?? Moderate improvement 30% reduction in ACR â?? Marked improvement	—

Measure

Time frame

Reduction in urinary albumin excretion from the base line. 20 % reduction in ACR â?? Mild improvement 30 % reduction in ACR â?? Moderate improvement 30% reduction in ACR â?? Marked improvementTimepoint: Reduction in urinary albumin excretion from the base line. 20 % reduction in ACR â?? Mild improvement 30 % reduction in ACR â?? Moderate improvement 30% reduction in ACR â?? Marked improvement

—

Secondary

Measure	Time frame
NilTimepoint: Nil	—

Countries

India

Contacts

Public ContactDr R Menaka

Govt Siddha Medical College

drkkanakavalli@gmail.com9444122865

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026